MS

Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study
Fierce Pharma
Roche
MS
multiple sclerosis
Ocrevus
FDA
vaccines
Flag link:
Celgene's timeline for refiling ozanimod gets mixed reviews
Celgene's timeline for refiling ozanimod gets mixed reviews
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
FDA
Flag link:
A metabolite will make or break Celgene's ozanimod
A metabolite will make or break Celgene's ozanimod
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
metabolite
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
CP Wire
Celgene
ozanimod
relapsing multiple sclerosis
MS
Flag link:
Lemtrada Treatment Effects in MS Patients Maintained Over Seven Years
Lemtrada Treatment Effects in MS Patients Maintained Over Seven Years
CP Wire
Sanofi Genzyme
Lemtrada
MS
Relapsing Remitting Multiple Sclerosis
Flag link:
Novartis pads case for new MS blockbuster with disease-progression analysis
Novartis pads case for new MS blockbuster with disease-progression analysis
Fierce Pharma
Novartis
MS
multiple sclerois
siponimod
Flag link:
Mylan and Mapi Pharma Partner on Once Monthly Glatiramer Acetate Drug for Relapsing-Remitting MS
Mylan and Mapi Pharma Partner on Once Monthly Glatiramer Acetate Drug for Relapsing-Remitting MS
CP Wire
Mylan Labs
Mapi Pharma
GA Depot
MS
Relapsing Remitting Multiple Sclerosis
Flag link:
Roche Acquires MS Remyelination Program from Versant Ventures
Roche Acquires MS Remyelination Program from Versant Ventures
CP Wire
Roche
MS
multiple sclerosis
remylination
M&A
Versant Ventures
Inception 5
Flag link:
Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet
Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet
CP Wire
Novartis
siponimod
clinical trials
MS
multiple sclerosis
SPMS
Flag link:
Biogen, AbbVie yank MS drug Zinbryta off the market in the wake of encephalitis cases
Biogen, AbbVie yank MS drug Zinbryta off the market in the wake of encephalitis cases
Endpoints
Biogen
AbbVie
MS
multiple sclerosis
Zinbryta
Europe
encephalitis
Flag link:
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Stat
Celgene
FDA
MS
multiple sclerosis
ozanimod
Flag link:
Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter
Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter
Motley Fool
Celgene
etrasimod
ozanimod
Arena Pharmaceuticals
MS
multiple sclerois
Flag link:
Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
Endpoints
Novartis
Momenta Pharmaceuticals
FDA
Copaxone
Teva Pharmaceutical
Glatopa
MS
multiple sclerosis
Flag link:
Will Teva Pharmaceutical's Pain Be Mylan's Gain?
Will Teva Pharmaceutical's Pain Be Mylan's Gain?
Motley Fool
Teva Pharmaceutical
Mylan Labs
Copaxone
generics
MS
multiple sclerosis
Flag link:
Multiple Sclerosis Drug Could be Safer for Patients if Dosing Intervals are Extended, Says Study
Multiple Sclerosis Drug Could be Safer for Patients if Dosing Intervals are Extended, Says Study
Xtalks
MS
multiple sclerosis
dosing
PML
Flag link:
Roche granted approval for ocrelizumab (multiple sclerosis) in Europe
Roche granted approval for ocrelizumab (multiple sclerosis) in Europe
GoinPharma
Roche
ocrelizumab
Europe
MS
multiple sclerosis
Flag link:
Look out, Teva: Mylan's Copaxone copy has already captured serious share
Look out, Teva: Mylan's Copaxone copy has already captured serious share
Fierce Pharma
Teva Pharmaceutical
Mylan Labs
Copaxone
generics
MS
multiple sclerosis
Flag link:
Biogen set to raise $300M from New Year's price hikes, just enough to offset MS competition
Biogen set to raise $300M from New Year's price hikes, just enough to offset MS competition
Fierce Pharma
Biogen
MS
multiple sclerosis
drug pricing
Flag link:
Biogen inks outcomes-based contract for MS meds
Biogen inks outcomes-based contract for MS meds
BioPharma Dive
Biogen
MS
multiple sclerosis
Prime Therapeutics
PBMs
Flag link:
Most Impressive Drug Launch: Roche's Ocrevus
Most Impressive Drug Launch: Roche's Ocrevus
BioPharma Dive
Roche
Ocrevus
drug launches
MS
multiple sclerosis
Flag link:

Pages